论文部分内容阅读
[目的]观察非小细胞肺癌(NSCLC)患者血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)和肿瘤坏死因子α(TNF-α)与NSCLC临床特征的相关性,探讨三者在NSCLC疗效评价中的临床价值。[方法]采用双抗体夹心酶联免疫吸附法(ELISA)检测NSCLC患者化疗前1d、化疗结束1周后血清VEGF、bFGF和TNF-α的含量。[结果]NSCLC患者化疗前血清VEGF、bFGF和TNF-α与患者临床分期有关(P<0.05),与患者年龄、性别及病理类型无关;分析68例晚期NSCLC患者化疗前后血清VEGF、bFGF和TNF-α的变化,临床获益组与疾病进展组比较三者均有明显下降(P<0.05)。[结论]血清VEGF、bFGF和TNF-α与NSCLC肿瘤负荷有关;血清VEGF、bFGF和TNF-α水平可作为NSCLC患者化疗疗效预测的参考指标。
[Objective] To investigate the correlation between serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and tumor necrosis factor-α (TNF-α) and the clinical features of NSCLC in patients with non-small cell lung cancer The clinical value of the three in the evaluation of NSCLC efficacy. [Methods] The serum levels of VEGF, bFGF and TNF-α in NSCLC patients were detected by ELISA before and 1 day after chemotherapy. [Results] The serum levels of VEGF, bFGF and TNF-α in patients with NSCLC before chemotherapy were correlated with the clinical stage (P <0.05), but not with age, sex and pathological type. The serum levels of VEGF, bFGF and TNF -α changes in clinical benefit group and disease progression group were significantly decreased compared with the three (P <0.05). [Conclusion] The serum levels of VEGF, bFGF and TNF-α are correlated with the tumor burden of NSCLC. The levels of serum VEGF, bFGF and TNF-α may be used as predictors for the response to chemotherapy in NSCLC patients.